Vivos Primær funksjon: Oftalmisk kirurgisystem av Olcayto Guelec and David Geuder

Designet Vivos Primær funksjon: Oftalmisk kirurgisystem av Olcayto Guelec and David Geuder er en høyt verdsatt vinner av den svært prestisjetunge 2026 A' Design Award i Gull i konkurransekategorien Medisinsk utstyr og medisinsk apparatdesign.

GullMedisinsk produkt· 2026

Vivos Primær funksjon: Oftalmisk kirurgisystem

av Olcayto Guelec and David Geuder

Klient: Geuder AG

Vinner av A' Design Award i Gull i kategorien Medisinsk produkt

56,783

Verifisert prisvinner

Verifiser prisstatus for #182492

Se på A' Design Award Pressemelding Prismerke

Farger

Designet

Om Vivos Primær funksjon: Oftalmisk kirurgisystem

Boktekst: Vivos redefinerer den kirurgiske arbeidsstasjonen som en plattform som utvikler seg i takt med kliniske ambisjoner. Tre konfigurasjoner, Core, Nova og Nova+, utvider kapasiteten uten å måtte bytte ut systemet, den eneste oppgraderingsarkitekturen av sitt slag innen oftalmisk kirurgi. Et enkelt grensesnitt, validert med 91,7 prosent tilfredshet ved førstegangsbruk uten forutgående opplæring, gjenspeiler en design bygget rundt kirurgen fremfor prosedyren. Opplyste instrumenttilkoblinger, foredlede materialer og tilbakeholden detaljering gir enheten et rolig og selvsikkert nærvær, fritt for den visuelle støyen som er typisk for kategorien.

Anerkjennelsen

Om A' Design Award i Gull

Vivos Primær funksjon: Oftalmisk kirurgisystem er vinner av A' Design Award i Gull, en enormt prestisjefylt anerkjennelse som tildeles førsteklasses, praktfulle og enestående design. Gullvinnere er usedvanlig nyskapende, visjonære og glamorøst blendende skaperverk som gjenspeiler designernes geni, visdom og dyktighet. Vivos Primær funksjon: Oftalmisk kirurgisystem forventes å være en høyt rost, trendsettende og monumental oppfinnelse som gir enestående verdi. Dette designet, som har vunnet A' Design Award i Gull, er et spektakulært, respektert prosjekt som i høy grad gagner og flytter grensene for kunst, vitenskap, design og teknologi. Vivos Primær funksjon: Oftalmisk kirurgisystem skaper intense følelser av begjær, vekker lidenskap, oppmuntrer til kreativitet og fascinerer oss.

Bak designet

Pressepakke

Krediteringer, teammedlemmer og tekniske detaljer levert av designeren.

Unike egenskaper: Vivos is the only ophthalmic surgery system that grows with clinical needs. Core for cataract. Nova adds vitrectomy. Plus adds laser. One platform. One interface. One training investment. Independent usability validation confirmed 92 percent user satisfaction among first time users. Illuminated connection sockets were rated positively by all study participants. Premium materials and restrained detailing give the device a likeable presence without the visual noise typical of the category.
Dimensjoner og emballasje: Display: 24 inch capacitive touchscreen. Vitrectomy: up to 40000 cuts per min. Vacuum: up to 700 mmHg, highest in category. Phacoemulsification: 53 kHz piezoelectric. IOP: active real-time (VIVOS Balance). Endolaser: 532 nm. Illumination: SOLEA LED, 16.9M colours, 2 ports, Retina Protection Mode. CE pending, submitted Feb 2026. ISO 13485 2016.
Stikkord: Ophthalmic Surgery System, Medical Device Design, Phacoemulsification, Vitrectomy, Modular Medical Platform, Surgical Ergonomics, Workflow Design, German Medical Engineering, Usability Validation, Premium Medical Aesthetics
Produksjonsteknologi: Medical-grade polycarbonate housing, antimicrobial surface coating rated for over 10,000 disinfection cycles. Piezoelectric phacoemulsification at 53 kHz with beveled-up probe geometry for optimised fluidics. Pneumatic vitrectomy probe up to 40,000 cuts/min. IEC 60601-1 compliant. Modular quick-change cassette - single or multi-patient - tool-free exchange. Compatible with older phaco handpieces, protecting prior investment. Individually assembled in Heidelberg. ISO 13485:2016, IEC 62366-1, IEC 60601-1, CE pending
Designutfordring: The central challenge was integrating six surgical functions, historically distributed across two to three separate devices, into a single platform without increasing cognitive load. Internally, decades of segmented product architecture and a 75-year heritage required rethinking established engineering logic. Externally, MDR regulations, IEC 62366 1 usability standards and strict OR hygiene constraints limited design freedom. Maintaining identical UX across Core, Nova and Plus while ensuring durability for thousands of cleaning cycles demanded systemic redesign rather than incremental improvement.
Forskning: Usability research was conducted. Objective: reduce cognitive load without limiting clinical capability. Methodology: iterative co-design workshops with surgeons, Geuder teams and engineering, followed by independent summative validation per IEC 62366-1. Data collection included usability testing and task-based evaluations. Participants: 13 first-time users at RWTH Aachen University, 2026. Results: 91.7% satisfaction, no unacceptable residual risks. Insights validated the workflow UI, surgeon profiles and illuminated sockets, contributing to greater efficiency, improved patient safety and long-term system adoption in clinical practice.
Inspirasjon: Ophthalmic surgery is precise. Why should its devices remain fragmented, complex and visually uninspiring. Anterior and posterior procedures require separate investments, training and ecosystems not because clinical need requires it but because no manufacturer redesigned the architecture around the surgeon. Geuder AG with seventy five years of ophthalmic expertise asked what if one platform could grow without hardware replacement. Validated by independent study and unique in its modular upgrade logic.
Prosjektvarighet: The project was developed in Heidelberg, Germany by Geuder AG. Development spanned multiple months with iterative design and engineering phases conducted in close collaboration with ophthalmic surgeons and operating room nursing staff. Summative usability validation was performed at RWTH Aachen University in early 2026. CE Mark application was submitted on 27 February 2026. Public market launch is scheduled for June 2026.
Driftsflyt: Before each procedure, the surgeon selects a personal profile, preloading preferred settings and pedal sensitivity. A three-column touchscreen maps each surgical step as a visual sequence. Colour-coded modules allow instant identification in a darkened theatre. Illuminated sockets guide instrument connection by touch. The foot pedal, with individually adjustable actuation force, controls fluid flow and laser hands-free. Eye pressure is monitored and adjusted in real time.
Teammedlemmer: Collaboration between Geuder AG's Engineering, Quality Management, Regulatory Affairs, Product Management, Service, Application, Development, and Sales departments.
Bildekreditering: Photography Geuder AG, 2026